Hyperlipidemia Treatment Market Analysis by Size, Share, Growth, Trends and Forecast 2030
Market Dynamics:
The global hyperlipidemia treatment
market exhibited
significant strength in 2021 and is poised to experience a rapid compound
annual growth rate (CAGR) in revenue over the forecast period. This growth is
attributed to the expanding target population and heightened awareness of the
cardiovascular disease (CVD) risks associated with persistent hyperlipidemia.
However, the global hyperlipidemia treatment market faces potential challenges
due to adverse effects associated with antihyperlipidemic medications.
Competitive Landscape:
Both organic and inorganic strategies are being employed by
companies in the market. For example, Akums Drugs & Pharmaceuticals
received authorization from DCGI and CDSCO to manufacture and market bempedoic
acid, a novel medicine for treating high LDL cholesterol levels. The US Food
and Drug Administration (FDA) approved Leqvio (inclisiran), developed by
Novartis, as the first and only siRNA therapy for lowering LDL cholesterol levels.
Major Companies in the Market:
• AstraZeneca
• Sun
Pharmaceutical Industries Ltd.
• Pfizer Inc.
• Johnson &
Johnson Private Limited
• Reckitt
Benckiser Group plc.
• Novartis AG
• Reddy’s
Laboratories Ltd
• GlaxoSmithKline
plc.
• Bristol-Myers
Squibb Company
• Eli Lilly and
Company
• Daiichi
Sankyo Company, Limited
• Amgen Inc.
Get a sample copy of the Hyperlipidemia Treatment Market report:
https://www.reportsanddata.com/download-free-sample/5257
Factors Supporting Market Growth:
Drivers: Numerous factors contribute to the growth of the
hyperlipidemia market. A survey conducted by the American Heart Association
reported a hyperlipidemia prevalence of 11.9%, with over 28.5 million
individuals aged 20 and above having high cholesterol levels. The number of
adults diagnosed with hyperlipidemia in the U.S. and Europe has exceeded three
million and continues to rise. The increasing elderly and geriatric population
is expected to be a driving force behind market growth. The World Health
Organization predicts that the global geriatric population, which was around
524 million in 2010, will reach approximately 2 billion by 2050. Moreover, the
growth of the market is influenced by hyperlipidemia guidelines in the U.S.,
particularly those addressing statin dosage regimens for individuals aged 21
and older at risk of developing Atherosclerotic Cardiovascular Disease (ASCVD).
This results in an expanding group of patients eligible for statin treatment.
Additionally, the growing diagnosis of hyperlipidemia, often due to unhealthy
dietary habits, contributes to market growth.
Restraints: Patients with hyperlipidemia exhibit a wide range
of responses to treatment, with many being intolerant to or unresponsive to
statins. These factors indirectly reduce the number of individuals using
statins for treatment. Anti-hyperlipidemic drugs are associated with various
gastrointestinal adverse effects that hinder market growth. The lack of trained
professionals for treatment and limited public awareness about this condition
are also barriers to market growth.
Opportunities: The expiration of the patent for drugs like
Vascepa by Amarin Corporation paves the way for the generic market. Increasing
research and development activities by pharmaceutical companies for targeted
hyperlipidemia treatments are expanding the market. Novel treatments, such as
human monoclonal antibodies like evolocumab and alirocumab, which block the
action of the proprotein convertase subtilisin-kexin type 9 Enzyme (PCSK-9),
are under study. PCSK-9 is a protein that binds to hepatic LDL receptors and
LDL cholesterol. Raising awareness and education about hyperlipidemia can
further drive market growth.
Hyperlipidemia encompasses various inherited and acquired
disorders characterized by abnormally high levels of lipids in the body. It is
a prevalent condition, especially in the Western hemisphere, but it also has a
global presence. Hyperlipidemia is typically defined as having Low-Density
Lipoprotein (LDL), total cholesterol, triglyceride levels, or lipoprotein
levels exceeding 90% of the population or having High-Density Lipoprotein (HDL)
levels lower than 10% of the population compared to the general populace.
Fastest-growing Region: The Asia Pacific market is projected
to register a significant CAGR in revenue over the forecast period. Countries
like China and India are witnessing substantial increases in their geriatric
populations. The presence of generic drug manufacturers and expanding
healthcare facilities will accelerate the region's growth rate.
End-Use Outlook (Revenue, USD Billion; 2019-2030):
- Hospital
Pharmacies
- Retailer
Pharmacies
- Online
Pharmacy Stores
Type Outlook (Revenue, USD Billion; 2019-2030):
- Familial
- Acquired
Route of Administration Outlook (Revenue, USD Billion;
2019-2030):
- Oral
- Parenteral
- Others
Treatment Outlook (Revenue, USD Billion; 2019-2030):
- Statins
- PCSK9
Inhibitors
- Bile
Acid Sequestrants
- Cholesterol
Absorption Inhibitors
- Fibric
Acid Derivatives
- Combination
- Others
Dosage Form Outlook (Revenue, USD Billion; 2019-2030):
- Tablets
- Injections
- Others
Regional Outlook (Revenue, USD Billion; 2019-2030):
- North
America (U.S., Canada, Mexico)
- Europe
(Germany, UK, France, Italy, Spain, Benelux, Rest of Europe)
- Asia
Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
- Latin
America (Brazil, Rest of Latin America)
- Middle
East & Africa (Saudi Arabia, UAE, South Africa)
Explore Trending Reports:
Smart
Governments Market-https://www.globenewswire.com/news-release/2019/12/17/1961293/0/en/Smart-Governments-Market-To-Reach-USD-52-19-Billion-By-2026-Reports-And-Data.html
Procure To
Pay Software Market-https://www.globenewswire.com/news-release/2019/09/05/1911800/0/en/Procure-To-Pay-Software-Market-To-Reach-USD-9-2-Billion-By-2026-Reports-And-Data.html
Advanced
Metering Infrastructure Market-https://www.globenewswire.com/news-release/2020/03/05/1996060/0/en/Advanced-Metering-Infrastructure-Market-To-Reach-USD-21-05-Billion-By-2026-Reports-And-Data.html
Request a customization of the report: https://www.reportsanddata.com/request-customization-form/5257
Thank
you for reading our report. To know more about the customization or any query
about the report contents, please connect with us and our team will ensure the
report is tailored to meet your requirements.
About Reports and Data
Reports
and Data is a market research and consulting company that provides syndicated
research reports, customized research reports, and consulting services. Our
solutions purely focus on your purpose to locate, target, and analyse consumer
behaviour shifts across demographics, across industries, and help clients to
make smarter business decisions. We offer market intelligence studies ensuring
relevant and fact-based research across multiple industries, including
Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update
our research offerings to ensure our clients are aware of the latest trends
existent in the market. Reports and Data has a strong base of experienced
analysts from varied areas of expertise. Our industry experience and ability to
develop a concrete solution to any research problems provides our clients with
the ability to secure an edge over their respective competitors.
Contact Us:
John W
(Head of Business Development)
Reports and Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
Blogs | Press Release | Industry News | Our competencies
Browse More Upcoming Reports @ https://www.reportsanddata.com/upcoming-reports
Browse More Latest Reports @ https://www.reportsanddata.com/report
Browse Latest Blogs: https://www.reportsanddata.com/blogs
Browse Latest Press
Release: https://www.reportsanddata.com/press-release
Comments
Post a Comment